SkinBioTherapeutics Debt 2024

SkinBioTherapeutics Aktienanalyse

What does SkinBioTherapeutics do?

SkinBioTherapeutics PLC is an innovative biotechnology company specialized in the development of skincare products. The company was founded in 2016 in Manchester, United Kingdom, and has since been led by a team of experienced scientists and entrepreneurs. The company's CEO, Dr. Catherine O'Neill, founded SkinBioTherapeutics PLC with the goal of developing innovative skincare products based on the latest scientific findings. The company focuses on the development of products using probiotic bacteria, which have been found to influence the immune system. SkinBioTherapeutics PLC is divided into three divisions: skincare, medical applications, and cosmetics. The skincare division develops products specifically tailored to the needs of individuals with sensitive and problematic skin, aiming to improve the skin's immune system and reduce inflammation and irritation. The medical applications division focuses on the use of probiotic bacteria in treating skin conditions such as psoriasis, eczema, and acne. The cosmetics division, under the brand "SkinBiotix," develops products to improve skin health and appearance. Currently, SkinBioTherapeutics PLC offers several products, including SkinBiotix Balance, a skincare cream for sensitive and problematic skin, SkinBiotix Cleanse, a gentle water-based cleanser, and SkinBiotix Strengthen, a rich moisturizer for dry and problematic skin. With its unique technology platform and strong emphasis on research and development, SkinBioTherapeutics PLC is well-positioned to continue growing and bringing its innovative products to market. SkinBioTherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding SkinBioTherapeutics's Debt Structure

SkinBioTherapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing SkinBioTherapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to SkinBioTherapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in SkinBioTherapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about SkinBioTherapeutics Stock

What is the debt of SkinBioTherapeutics this year?

SkinBioTherapeutics has a debt level of -1.21 GBP this year.

What was the debt of SkinBioTherapeutics compared to the previous year?

The debt of SkinBioTherapeutics has increased by -27.78% compared to the previous year dropped.

What are the consequences of high debt for investors in SkinBioTherapeutics?

High debt can pose a risk for investors of SkinBioTherapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of SkinBioTherapeutics?

Low debt means that SkinBioTherapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from SkinBioTherapeutics affect the company?

An increase in debt of SkinBioTherapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of SkinBioTherapeutics affect the company?

A reduction in debt of SkinBioTherapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of SkinBioTherapeutics?

Some factors that can influence the debt of SkinBioTherapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of SkinBioTherapeutics so important for investors?

The debts of SkinBioTherapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can SkinBioTherapeutics take to change the debt?

To change the debt, SkinBioTherapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does SkinBioTherapeutics pay?

Over the past 12 months, SkinBioTherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SkinBioTherapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of SkinBioTherapeutics?

The current dividend yield of SkinBioTherapeutics is .

When does SkinBioTherapeutics pay dividends?

SkinBioTherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SkinBioTherapeutics?

SkinBioTherapeutics paid dividends every year for the past 0 years.

What is the dividend of SkinBioTherapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is SkinBioTherapeutics located?

SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von SkinBioTherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SkinBioTherapeutics from 6/6/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did SkinBioTherapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of SkinBioTherapeutics in the year 2023?

In the year 2023, SkinBioTherapeutics distributed 0 GBP as dividends.

In which currency does SkinBioTherapeutics pay out the dividend?

The dividends of SkinBioTherapeutics are distributed in GBP.